Skip to content

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

Uncategorized

New Releases from NCBI BookshelfPhysician Productivity in Specialty Care: A Scoping Review.Physician Productivity in Specialty Care: A Scoping Review.

Leave a Comment / Uncategorized / admin

The purpose of this report was to review the available evidence on physician productivity measures. This report was requested by […]

New Releases from NCBI BookshelfRozanolixizumab (Rystiggo): Indication: For the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive: Reimbursement Recommendation [Internet].Rozanolixizumab (Rystiggo): Indication: For the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized / admin

Canada’s Drug Agency (CDA-AMC) recommends that public drug plans reimburse Rystiggo as an add-on therapy for the treatment of adult

New Releases from NCBI BookshelfAlternate Level of Care in Canada: Evidence Assessment Report: Health Systems [Internet].Alternate Level of Care in Canada: Evidence Assessment Report: Health Systems [Internet].

Leave a Comment / Uncategorized / admin

Alternate level of care (ALC) is a designation used and applied by clinical staff to the portion of a patient’s

New Releases from NCBI BookshelfTrastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies.Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfBlinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal).Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal).

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfExagamglogene Autotemcel (Casgevy): Therapeutic area: Transfusion-dependent beta thalassemia: Reimbursement Review [Internet].Exagamglogene Autotemcel (Casgevy): Therapeutic area: Transfusion-dependent beta thalassemia: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfAcalabrutinib for treating chronic lymphocytic leukaemia.Acalabrutinib for treating chronic lymphocytic leukaemia.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfMepolizumab for treating severe eosinophilic asthma.Mepolizumab for treating severe eosinophilic asthma.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfAnakinra for treating Still’s disease.Anakinra for treating Still’s disease.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfNivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease.Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease.

Leave a Comment / Uncategorized / admin

Post Content

← Previous 1 … 67 68 69 … 217 Next →

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top